Comparative cost analysis of implanting devices in different cardiac resynchronization therapeutic strategies

Mengna Chen, Jing Shi, Yimin Zhang, Xiaozhen Ge, Xu Zhang, Wenbin Fan, Shuo Wang, Zhiqin Guo, Jian Guan, Yongquan Wu, Junmeng ZhangClinical 2023 · DOI

TL;DR

This study compares the cost-effectiveness of different cardiac resynchronization therapy (CRT) strategies. It finds that conduction system pacing (CSP)-based CRT, utilizing less expensive conventional pacemakers, is significantly more cost-effective than traditional biventricular pacing (BVP)-based CRT, which requires costly triple-chamber devices. This offers a more accessible CRT option for heart failure patients.

What Problem Does This Paper Address?

Heart failure (HF) patients with specific conditions like broad QRS duration and reduced ejection fraction often benefit from cardiac resynchronization therapy (CRT). However, the standard CRT approach, biventricular pacing (BVP), relies on expensive triple-chamber pacemakers (CRT-P or CRT-D). This high cost limits its adoption, leaving many eligible patients without this life-improving treatment. While newer methods like His-Purkinje system pacing (HPSP), also known as conduction system pacing (CSP), can achieve CRT using more affordable dual- or single-chamber pacemakers, a direct cost comparison with BVP-based CRT has been lacking. This paper aims to fill that gap by providing a comparative cost analysis to guide clinical decisions, especially for patients with financial constraints.

Methods

The researchers collected data on the prices, designed lives, and calculated the price-per-designed-life for various mainstream pacemaker models sold in the Chinese market in 2022. This included CRT-P, CRT-D, dual-chamber, and single-chamber pacemakers from major manufacturers like Medtronic, Abbott, Boston Scientific, and Biotronik. Prices were converted to USD for comparison. Statistical analysis, including one-way ANOVA and t-tests, was used to compare the groups and determine statistical significance (p < .05).

Datasets

The study utilized pricing and designed life data for commercially available pacemaker models in the Chinese market in 2022. Specific datasets include:

  • CRT-P models (n=8)
  • CRT-D models (n=9)
  • Dual-chamber pacemaker models (n=11)
  • Single-chamber pacemaker models (n=9)

No new benchmarks were introduced; the study focused on analyzing existing market data.

Key Insights and Ideas

  • Cost is a Major Barrier: The high cost of triple-chamber pacemakers is a significant factor limiting the widespread use of BVP-based CRT, even though it's an established and effective therapy.
  • CSP Offers a Cost-Effective Alternative: Conduction system pacing (CSP), which can be achieved with conventional dual- or single-chamber pacemakers, presents a substantially more affordable approach to CRT.
  • Designed Life Matters for Cost: While triple-chamber pacemakers are more expensive upfront, their shorter designed lifespan compared to conventional pacemakers further increases their long-term cost of ownership.
  • Tailoring Treatment to Patient Needs: For patients who don't require defibrillation capabilities, CSP-based CRT with conventional pacemakers emerges as a highly attractive and cost-effective option.

Key Results

  • Price: CRT-D devices were the most expensive (average $22,043.36 USD), followed by CRT-P ($13,008.44 USD). Conventional dual-chamber pacemakers were less expensive ($11,142.39 USD), and single-chamber pacemakers were the most affordable ($5,634.28 USD). All these differences were statistically significant (p < .05).
  • Designed Life: Conventional pacemakers (dual-chamber: 13.18 ± 2.09 years; single-chamber: 13.11 ± 3.79 years) generally had longer designed lives than triple-chamber pacemakers (CRT-P: 9.38 ± 1.06 years; CRT-D: 8.61 ± 0.78 years). These differences were also statistically significant (p < .05).
  • Price/Designed Life (Cost-Effectiveness): Single-chamber pacemakers offered the best cost-effectiveness ($435.86 ± 125.44 USD/year), followed by dual-chamber pacemakers ($839.63 ± 258.62 USD/year). CRT-P ($1386.91 ± 266.73 USD/year) and CRT-D ($2585.53 ± 520.27 USD/year) were significantly less cost-effective.

Limitations and Future Work

The authors acknowledge that their study included only some pacemaker models, which may introduce some bias. Pacemaker prices are also influenced by local healthcare policies. Future work could expand the analysis to include a wider range of models and consider regional price variations. The study also highlights that CSP-CRT is not suitable for all patients, particularly those requiring atrioventricular synchronized pacing, and is best suited for a minority of patients with specific conditions like atrial fibrillation.

Summary updated

Abstract

Conduction system pacing (CSP)-based CRT is more cost-effective than BVP-based CRT. Furthermore, CSP-based CRT can achieve cardiac resynchronization with conventional pacemakers and may be a good option for HF patients who do not need defibrillation.
BibTeX
@inproceedings{chen2023comparative,
  author = {Mengna Chen and Jing Shi and Yimin Zhang and Xiaozhen Ge and Xu Zhang and Wenbin Fan and Shuo Wang and Zhiqin Guo and Jian Guan and Yongquan Wu and Junmeng Zhang},
  title = {{Comparative cost analysis of implanting devices in different cardiac resynchronization therapeutic strategies}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1002/clc.24107},
}
Figure